Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA scheduling updates include the temporary placement of 2-Fluorodeschloroketamine in Schedule I due to its abuse potential. This regulatory action highlights challenges in controlling novel synthetic substances. Clinicians should stay informed…
Schedules of Controlled Substances: Diphenidine Schedule I Placement
The DEA has placed diphenidine into Schedule I due to its abuse potential and lack of medical use. This diphenidine schedule I placement highlights challenges in regulating novel synthetic drugs. Clinicians should screen for diphenidine use alongside…
Policy Watch: 20 Regulatory Updates — June 06, 2026
Policy WatchJune 06, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Policy Watch: 20 Regulatory Updates — June 02, 2026
Policy WatchJune 02, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has designated synthetic cannabinoids schedule I designation for CUMYL-PEGACLONE due to its high abuse potential and no accepted medical use. This scheduling reflects ongoing regulatory efforts to control novel synthetic cannabinoids. Clinicians…
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA has placed diphenidine in Schedule I, classifying it as a controlled substance with high abuse potential. Diphenidine is a synthetic dissociative drug posing public health risks. Awareness of diphenidine schedule I status aids clinicians in…